Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Morphic Holding, Inc. - Common Stock (NQ:MORF)

56.99 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Morphic Holding, Inc. - Common Stock

< Previous 1 2 3 Next >
Will MORPHIC HOLDING INC Break Out? A Technical Analysis Perspective.
Investors are keeping a close eye on MORPHIC HOLDING INC (NASDAQ:MORF) as it boasts an impressive technical rating of 9 out of 10, signaling a possible breakout. 
Via Chartmill
MORF Stock Earnings: Morphic Holding Misses EPS for Q2 2024
MORF stock results show that Morphic Holding missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Americans Are Flying; Airline Stocks Are Not
How the airline industry's focus on capacity and being able to supply more flights means fares are low, even in the face of record demand. 
Via The Motley Fool
3 Stocks for Patient Investors Looking to Build Generational Wealth
Investing in generational wealth stocks means holding them for years, preferably decades, to allow them to deliver supercharged returns. 
Via InvestorPlace
Russell 2000 Index Notches Strongest Week Of Year, Hits 31-Month Highs: Outlook Is 'Clouded By Fed's Concerns Over Labor Market,' Analyst Warns
The Russell 2000 index of small caps recorded its best weekly performance since October 2023, surging over 6%, driven by lower-than-expected June inflation data and potential interest rate cuts. 
Via Benzinga
Topics Economy
Recap: Morphic Holding Q4 Earnings
Via Benzinga
Where Morphic Holding Stands With Analysts
Via Benzinga
Stock Market Shifts Toward Small Caps After Tame CPI; JPMorgan, Taiwan Semi, Tesla In Focus: Weekly Review
Megacaps and chip plays tumbled Thursday, but mostly still have healthy charts. 
Via Investor's Business Daily
Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst
Eli Lilly's acquisition of Morphic highlights strategic expansion in Immunology, targeting α4β7 for ulcerative colitis and Crohn's disease treatments. Goldman Sachs notes the deal's potential to... 
Via Benzinga
Hot Stocks: 3 Sleeping Giants About to Dominate Their Sectors
Give some consideration to these names, each of which has a strong competitive advantage and catalysts driving their share price higher. 
Via InvestorPlace
S&P 500 Closes At Record High Ahead Of Inflation Data: Fear & Greed Index Remains In 'Neutral' Zone
The CNN Money Fear and Greed index slightly decreased, remaining in Neutral zone. US stocks mixed, with S&P 500 at record high. 
Via Benzinga
Topics Economy Stocks
Patients Lost More Weight On Eli Lilly's Mounjaro Than Novo Nordisk's Ozempic
Patients lost more more weight on Mounjaro than Ozempic. 
Via Investor's Business Daily
Gold Falls Over 1%; HilleVax Shares Plunge
Via Benzinga
Stocks Hold Steady, Small Caps Rise, French Equities Slip After Surprise Win By Left-Wing Bloc: What's Driving Markets Monday?
U.S. stocks started the week on a neutral note, with the S&P 500 and Nasdaq 100 indices hovering around the flatline by midday trading in New York. This comes after both indices reached fresh record... 
Via Benzinga
Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Dow Turns Lower; Myomo Shares Jump
Via Benzinga
Topics Stocks
Microsoft Layoffs 2024: What to Know as MSFT Enacts More Job Cuts
Microsoft layoffs hit the tech giant's employees last week as it reduced an unknown number of roles in two of its divisions. 
Via InvestorPlace
Topics Workforce
NVDA Stock Warning: EU Watchdogs Are Sizing Up Nvidia
Nvidia stock is up on Monday even as investors in NVDA learn of warnings from EU regulators over its AI chip supply bottleneck. 
Via InvestorPlace
Topics Artificial Intelligence
Why Is Morphic (MORF) Stock Up 75% Today?
Morphic stock is up on Monday after the company signed a deal with Eli Lilly for the acquisition of MORF shares at $57 each in cash. 
Via InvestorPlace
Corning Increases Sales Forecast, Joins Morphic Holding, Lucid Group And Other Big Stocks Moving Higher On Monday
Via Benzinga
Dow Jumps Over 200 Points; Greenbrier Shares Fall After Q3 Results
Via Benzinga
Topics Stocks
Eli Lilly's First Biotech Deal Of 2024, Buys Chronic Disease Player Morphic For $3.2B
Eli Lilly to acquire Morphic Holding Inc for $3.2 billion, strengthening its portfolio in chronic disease treatments. Morphic's lead program, MORF-057, targets inflammatory bowel disease, with... 
Via Benzinga
Eli Lilly Snaps Up Morphic At 79% Premium
Eli Lilly said Monday it would pay $3.2 billion to acquire an innovator in oral treatments for chronic bowel diseases. 
Via Investor's Business Daily
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the week with a breakdown of the biggest pre-market stock movers traders will want to know about on Monday! 
Via InvestorPlace
MORF Stock Earnings: Morphic Holding Beats EPS for Q1 2024
MORF stock results show that Morphic Holding beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Stock Market Rally Attempt Underway; Micron, Nike, Amazon, Meta In Focus: Weekly Review
But it's not a confirmed uptrend yet. Nike, Amazon and Meta were in focus. 
Via Investor's Business Daily
Gold Moves Lower; TransCode Therapeutics Shares Surge
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher by around 30 points on Monday. The Dow traded down 0.07% to 33,939.93 while the NASDAQ rose 0.24% to... 
Via Benzinga
Topics Stocks
Morphic Therapeutic's Stock Plunges On Monday - Here's Why?
Since Friday, Morphic Therapeutic (NASDAQ: MORF) shares have plunged from $47.92 to $26.25 after the company announced the publication of an abstract discussing new EMERALD-1 phase 2a primary results... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138. 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.